{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T13:17:52Z","timestamp":1794489472858,"version":"4.9.1"},"reference-count":36,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,11,6]],"date-time":"2020-11-06T00:00:00Z","timestamp":1604620800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100005062","name":"Fujirebio Europe","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005062","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","gynecologiconcology-online.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gynecologic Oncology"],"published-print":{"date-parts":[[2021,2]]},"DOI":"10.1016\/j.ygyno.2020.11.004","type":"journal-article","created":{"date-parts":[[2020,11,16]],"date-time":"2020-11-16T18:12:23Z","timestamp":1605550343000},"page":"514-519","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":25,"title":["HE4 and CA125 as preoperative risk stratifiers for lymph node metastasis in endometrioid carcinoma of the endometrium: A retrospective study in a cohort with histological proof of lymph node status"],"prefix":"10.1016","volume":"160","author":[{"given":"Sharon A.","family":"O'Toole","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanmei","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucy","family":"Norris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Megan","family":"Power Foley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rizmee","family":"Shireen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seamus","family":"McDonald","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Waseem","family":"Kamran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadia","family":"Ibrahim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Ward","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claire","family":"Thompson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cliona","family":"Murphy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tom","family":"D'Arcy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadine","family":"Farah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"Heron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John J.","family":"O'Leary","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feras","family":"Abu Saadeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noreen","family":"Gleeson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ygyno.2020.11.004_bb0005","doi-asserted-by":"crossref","first-page":"E359","DOI":"10.1002\/ijc.29210","article-title":"Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012","volume":"136","author":"Ferlay","year":"2015","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.ygyno.2020.11.004_bb0010","doi-asserted-by":"crossref","first-page":"1719","DOI":"10.1002\/ijc.31961","article-title":"Risk factors for endometrial cancer: an umbrella review of the literature","volume":"145","author":"Raglan","year":"2019","journal-title":"Int. J. Cancer"},{"issue":"Suppl. 1","key":"10.1016\/j.ygyno.2020.11.004_bb0015","first-page":"S105","article-title":"Carcinoma of the corpus uteri. FIGO 26th annual report on the results of treatment in gynecological cancer","volume":"95","author":"Creasman","year":"2006","journal-title":"Int. J. Gynaecol. Obstet."},{"key":"10.1016\/j.ygyno.2020.11.004_bb0020","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1111\/jog.12344","article-title":"Role of pelvic and Para-aortic lymphadenectomy in endometrial cancer: current evidence","volume":"40","author":"Bogani","year":"2014","journal-title":"J. Obstet. Gynaecol. Res."},{"key":"10.1016\/j.ygyno.2020.11.004_bb0025","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/S0140-6736(08)61766-3","article-title":"Efficacy of systematic pelvic lymphadenectomy in endometrial cancer (MRC ASTEC trial): a randomised study","volume":"373","author":"Kitchener","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.ygyno.2020.11.004_bb0030","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1097\/AOG.0000000000002261","article-title":"Accuracy of endometrial sampling in endometrial carcinoma: a systematic review and meta-analysis","volume":"130","author":"Visser","year":"2017","journal-title":"Obstet. Gynecol."},{"key":"10.1016\/j.ygyno.2020.11.004_bb0035","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1007\/s11912-016-0506-0","article-title":"What is the best preoperative imaging for endometrial cancer?","volume":"18","author":"Haldorsen","year":"2016","journal-title":"Curr. Oncol. Rep."},{"key":"10.1016\/j.ygyno.2020.11.004_bb0040","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1097\/IGC.0000000000000919","article-title":"Incidence of lymph node metastasis in surgically staged FIGO IA G1\/G2 endometrial cancer with a tumor size of more than 2 cm","volume":"27","author":"Boyraz","year":"2017","journal-title":"Int. J. Gynecol. Cancer"},{"key":"10.1016\/j.ygyno.2020.11.004_bb0045","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.ygyno.2011.09.017","article-title":"Lymphovascular space invasion is an independent risk factor for nodal disease and poor outcomes in endometrioid endometrial cancer","volume":"124","author":"Guntupalli","year":"2012","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2020.11.004_bb0050","doi-asserted-by":"crossref","first-page":"e880","DOI":"10.1634\/theoncologist.2019-0117","article-title":"Diagnostic accuracy of clinical biomarkers for preoperative prediction of lymph node metastasis in endometrial carcinoma: a systematic review and meta-analysis","volume":"24","author":"Reijnen","year":"2019","journal-title":"Oncologist"},{"key":"10.1016\/j.ygyno.2020.11.004_bb0055","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/j.ygyno.2008.04.002","article-title":"Utility of a novel serum tumor biomarker HE4 in patients with endometrioid adenocarcinoma of the uterus","volume":"110","author":"Moore","year":"2008","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2020.11.004_bb0060","first-page":"548","article-title":"The emerging role of HE4 in the evaluation of epithelial ovarian and endometrial carcinomas","volume":"27","author":"Simmons","year":"2013","journal-title":"Oncology (Williston Park)"},{"key":"10.1016\/j.ygyno.2020.11.004_bb0065","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.ygyno.2013.10.036","article-title":"Serum HE4 as a prognostic marker in endometrial cancer--a population based study","volume":"132","author":"Brennan","year":"2014","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2020.11.004_bb0070","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.advms.2015.07.010","article-title":"Utility of HE4 to identify patients with endometrioid endometrial cancer who may require lymphadenectomy","volume":"61","author":"Dobrzycka","year":"2016","journal-title":"Adv. Med. Sci."},{"key":"10.1016\/j.ygyno.2020.11.004_bb0075","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.7314\/APJCP.2016.17.3.1489","article-title":"Association of Serum HE4 with primary tumor diameter and depth of Myometrial invasion in endometrial Cancer patients at Rajavithi hospital","volume":"17","author":"Prueksaritanond","year":"2016","journal-title":"Asian Pac. J. Cancer Prev."},{"key":"10.1016\/j.ygyno.2020.11.004_bb0080","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1111\/aogs.12235","article-title":"HE4 and CA125 levels in the preoperative assessment of endometrial cancer patients: a prospective multicenter study (ENDOMET)","volume":"92","author":"Antonsen","year":"2013","journal-title":"Acta Obstet. Gynecol. Scand."},{"key":"10.1016\/j.ygyno.2020.11.004_bb0085","first-page":"437468","article-title":"Expression of HE4 in endometrial cancer and its clinical significance","volume":"2015","author":"Li","year":"2015","journal-title":"Biomed. Res. Int."},{"key":"10.1016\/j.ygyno.2020.11.004_bb0090","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1002\/ijgo.13140","article-title":"HE4 tumor marker as a predictive factor for lymphatic metastasis in endometrial cancer","volume":"149","author":"Espiau Romera","year":"2020","journal-title":"Int. J. Gynaecol. Obstet."},{"key":"10.1016\/j.ygyno.2020.11.004_bb0095","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1007\/s13277-011-0256-4","article-title":"Human epididymis protein 4 reference limits and natural variation in a Nordic reference population","volume":"33","author":"Bolstad","year":"2012","journal-title":"Tumour Biol."},{"key":"10.1016\/j.ygyno.2020.11.004_bb0100","doi-asserted-by":"crossref","first-page":"2285","DOI":"10.1158\/1055-9965.EPI-14-0447","article-title":"HE4 tissue expression and serum HE4 levels in healthy individuals and patients with benign or malignant tumors: a systematic review","volume":"23","author":"Karlsen","year":"2014","journal-title":"Cancer Epidemiol. Biomark. Prev."},{"key":"10.1016\/j.ygyno.2020.11.004_bb0105","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1006\/gyno.1998.5018","article-title":"Determination of a normal level of serum CA125 in postmenopausal women as a tool for preoperative evaluation and postoperative surveillance of endometrial carcinoma","volume":"69","author":"Kurihara","year":"1998","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2020.11.004_bb0110","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1007\/s13277-012-0583-0","article-title":"The role of novel biomarker HE4 in endometrial cancer: a case control prospective study","volume":"34","author":"Angioli","year":"2013","journal-title":"Tumour Biol."},{"key":"10.1016\/j.ygyno.2020.11.004_bb0115","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1097\/IGC.0000000000000621","article-title":"Comparison of serum human epididymis protein 4 and carbohydrate antigen 125 as markers in endometrial cancer: a meta-analysis","volume":"26","author":"Hu","year":"2016","journal-title":"Int. J. Gynecol. Cancer"},{"key":"10.1016\/j.ygyno.2020.11.004_bb0120","doi-asserted-by":"crossref","first-page":"36","DOI":"10.23736\/S0026-4784.18.04328-9","article-title":"The role of human epididymis protein 4 as a biomarker in gynecologic malignancies","volume":"71","author":"Plotti","year":"2019","journal-title":"Minerva Ginecol."},{"key":"10.1016\/j.ygyno.2020.11.004_bb0125","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1007\/s00404-019-05276-9","article-title":"Risk factors for pelvic lymph node metastasis in endometrial cancer","volume":"300","author":"Li","year":"2019","journal-title":"Arch. Gynecol. Obstet."},{"key":"10.1016\/j.ygyno.2020.11.004_bb0130","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1002\/ijgo.12010","article-title":"Predictive value of serum HE4 and CA125 concentrations for lymphatic metastasis of endometrial cancer","volume":"136","author":"Wang","year":"2017","journal-title":"Int. J. Gynaecol. Obstet."},{"key":"10.1016\/j.ygyno.2020.11.004_bb0135","doi-asserted-by":"crossref","first-page":"2189","DOI":"10.1515\/cclm-2011-0757","article-title":"Human epididymis protein 4 as a serum marker for diagnosis of endometrial carcinoma and prediction of clinical outcome","volume":"50","author":"Zanotti","year":"2012","journal-title":"Clin. Chem. Lab. Med."},{"key":"10.1016\/j.ygyno.2020.11.004_bb0140","doi-asserted-by":"crossref","first-page":"1644","DOI":"10.1111\/jog.12764","article-title":"Prognostic value of human epididymis protein 4 in endometrial cancer and its utility for surgical staging","volume":"41","author":"Minar","year":"2015","journal-title":"J. Obstet. Gynaecol. Res."},{"key":"10.1016\/j.ygyno.2020.11.004_bb0145","doi-asserted-by":"crossref","first-page":"4973","DOI":"10.1007\/s13277-015-4324-z","article-title":"The role of HE4 in endometrial cancer recurrence: how to choose the optimal follow-up program","volume":"37","author":"Angioli","year":"2016","journal-title":"Tumour Biol."},{"key":"10.1016\/j.ygyno.2020.11.004_bb0150","doi-asserted-by":"crossref","first-page":"5733","DOI":"10.1158\/1078-0432.CCR-13-1376","article-title":"REM (risk of endometrial malignancy): a proposal for a new scoring system to evaluate risk of endometrial malignancy","volume":"19","author":"Angioli","year":"2013","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ygyno.2020.11.004_bb0155","first-page":"177","article-title":"Utility of pelvic MRI and tumor markers HE4 and CA125 to predict depth of myometrial invasion and cervical involvement in endometrial cancer","volume":"9","author":"Zamani","year":"2015","journal-title":"J Family Reprod Health"},{"key":"10.1016\/j.ygyno.2020.11.004_bb0160","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1002\/uog.21950","article-title":"An ultrasound-based risk model to predict lymph node metastases before surgery in women with endometrial cancer: a model development study","volume":"56","author":"Eriksson","year":"2020","journal-title":"Ultrasound Obstet. Gynecol."},{"key":"10.1016\/j.ygyno.2020.11.004_bb0165","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1007\/s13277-013-1190-4","article-title":"A critical review on HE4 performance in endometrial cancer: where are we now?","volume":"35","author":"Angioli","year":"2014","journal-title":"Tumour Biol."},{"key":"10.1016\/j.ygyno.2020.11.004_bb0170","doi-asserted-by":"crossref","first-page":"1534","DOI":"10.1373\/clinchem.2010.157073","article-title":"Comparison of serum human epididymis protein 4 with cancer antigen 125 as a tumor marker in patients with malignant and nonmalignant diseases","volume":"57","author":"Escudero","year":"2011","journal-title":"Clin. Chem."},{"key":"10.1016\/j.ygyno.2020.11.004_bb0175","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1258\/acb.2011.011258","article-title":"Elevated human epididymis protein 4 concentrations in chronic kidney disease","volume":"49","author":"Nagy","year":"2012","journal-title":"Ann. Clin. Biochem."},{"key":"10.1016\/j.ygyno.2020.11.004_bb0180","doi-asserted-by":"crossref","first-page":"2865","DOI":"10.1158\/1078-0432.CCR-15-2233","article-title":"Endometrial carcinomas with POLE exonuclease domain mutations have a favorable prognosis","volume":"22","author":"McConechy","year":"2016","journal-title":"Clin. Cancer Res."}],"container-title":["Gynecologic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825820341123?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825820341123?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T03:53:15Z","timestamp":1758772395000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090825820341123"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2]]},"references-count":36,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021,2]]}},"alternative-id":["S0090825820341123"],"URL":"https:\/\/doi.org\/10.1016\/j.ygyno.2020.11.004","relation":{},"ISSN":["0090-8258"],"issn-type":[{"value":"0090-8258","type":"print"}],"subject":[],"published":{"date-parts":[[2021,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"HE4 and CA125 as preoperative risk stratifiers for lymph node metastasis in endometrioid carcinoma of the endometrium: A retrospective study in a cohort with histological proof of lymph node status","name":"articletitle","label":"Article Title"},{"value":"Gynecologic Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ygyno.2020.11.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}